Iterum Therapeutics PLC
NASDAQ:ITRM

Watchlist Manager
Iterum Therapeutics PLC Logo
Iterum Therapeutics PLC
NASDAQ:ITRM
Watchlist
Price: 1.26 USD -3.08% Market Closed
Market Cap: 43.6m USD

Iterum Therapeutics PLC
Investor Relations

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. The company is headquartered in Dublin, Dublin and currently employs 13 full-time employees. The company went IPO on 2018-05-25. The firm is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The firm is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. The company is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. The firm also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid, which is known as oral sulopenem.

Show more
Loading

Earnings Calls

2025 Q3
Mar 5, 2025
Show Transcript
Previous
Next
Daktronics Sees Stable Margins Amidst Order Fluctuations, Targets Sustainable Growth
2025 Q3
Mar 5, 2025

In the third quarter of fiscal 2025, Daktronics faced a 12.2% drop in sales, influenced by seasonal declines, yet managed to maintain a gross profit margin of 24.6%. Orders grew 5.2% from the previous quarter, primarily in commercial sectors. The company anticipates revenue growth above the sector average of 7-10%, aiming for an operating margin of 10-12% and return on capital of 17-20% by fiscal 2028. Despite a challenging environment due to potential tariff impacts, their strategic initiatives and strong project backlog of $273 million position Daktronics for long-term success.

Show Full Analysis

Management

Mr. Corey N. Fishman
President, CEO & Director
No Bio Available
Ms. Judith M. Matthews
Chief Financial Officer
No Bio Available
Dr. Michael W. Dunne M.D.
Strategic Advisor & Director
No Bio Available
Mr. Tom Loughman Ph.D.
Senior Vice President of Technical Operations
No Bio Available
Ms. Louise Barrett
Senior Vice President of Legal Affairs & Secretary
No Bio Available
Dr. Steven I. Aronin M.D.
Senior VP & Head of Clinical Development
No Bio Available

Contacts

Address
DUBLIN
DUBLIN
Fitzwilliam Court, 1St Floor, Leeson Close
Contacts
+35316694820.0
www.iterumtx.com